Join the Oncology Voice Network. Join for Free
How Compliance Builds Trust in Cancer Care

How Compliance Builds Trust in Cancer Care


Share This Article


Summary

Discover how trust, culture, and teamwork lift oncology drug development to new heights.

In this episode of the Oncology Voice Network Podcast, Host Dr. Kirk Shepard interviews Tina Beamon, a respected legal and compliance leader whose career spans pharma, biotech, and patient advocacy. Drawing from firsthand experience, Tina shares her journey from editing patient stories at the height of the AIDS epidemic to helping launch life-changing oncology drugs. Together, they discuss the real difference between legal and compliance, reveal how compliance becomes a strategic advantage in drug development, and explain why an effective compliance program is all about organizational culture. Tina gives practical advice for early-stage companies and highlights how compliance empowers medical and commercial teams to collaborate safely and creatively—always with patients at the center. Learn why compliance should be at the table in every conversation, how to build trust with patient advocacy groups, and how leadership shapes the culture that patients rely on.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN